Positive Phase II/III trial data for lenacapavir in the treatment of adults with multidrug-resistant HIV
Lenacapavir is a long-acting HIV-1 capsid inhibitor. In the CAPELLA trial (n=36), a viral load reduction of at least 0.5 log10 copies/mL at the end of the 14-day study was achieved in more patients in the lenacapavir arm than the placebo arm (88% vs. 17%, respectively; p<0.0001).
Source:
Biospace Inc.
SPS commentary:
Lenacapavir is being developed as a component of a long-acting regimen in combination with other antiretrovirals for the treatment of HIV-1 infection. If approved, it would be the first HIV capsid inhibitor available for the treatment of HIV-1 infection. In May 2019, it was granted Breakthrough Therapy Designation in the US for the treatment of HIV-1 infection in heavily treatment-experienced patients with multidrug resistance in combination with other antiretrovirals.